Abstract:ID 129061 Poster Board 491 Background: Brilaroxazine, a novel multimodal neuromodulator, belongs to a class of next-generation treatments for schizophrenia and comorbid conditions. It functions as a D 2/3/4 and 5-HT 1A/2A partial agonist and a 5 HT 2B/7 antagonist with binding affinity for 5-HT 2B > D 2 . It also mediates inflammatory cytokines. With defined efficacy, safety, and pharmacokinetics from clinical trials, it offers a differentiated profile over other antipsychotics. Brilaroxazine's development involved rats, mice, and dogs for nonclinical toxicological evaluations. This study evaluated the absorption, metabolism, and excretion of brilaroxazine in rats after a single 14 C-brilaroxazine dose to qualify rats as a suitable toxicology species. Methods: This study involved 12 male Sprague Dawley rats divided equally into three groups. These animals received a single [ 14 C]-brilaroxazine 20 mg/kg (200 mCi/kg) oral dose. Group 1 rats had a bile-duct cannula (BDC) surgically implanted for bile and feces collection. Group 2 rats had blood collected for metabolite evaluation. Group 3 rats had urine and feces collected to determine the mass balance. Maximal post-dose collection times for bile samples were 72 hours (Group 1), serial blood samples were 72 hours (Group 2), and urine and feces samples were 168 hours (Group 3). Sample analysis included liquid scintillation counting (LSC) or a combustion/ LSC combination (blood, plasma, and excreta), validated liquid chromatography–mass spectrometry/mass spectrometry (unlabeled brilaroxazine and RP5081 plasma concentrations), and mass spectral analysis or direct comparison with authentic standards for metabolite structures (brilaroxazine, and metabolite RP5081). Results: Bile or feces of BDC rats or intact rats were the predominant routes for dose radioactivity excretion. The percent of the administered dose recovered in Group 1 BDC rat bile, feces, and urine accounted for 79.52%, 13.02%, and 5.60%, respectively. Bile and urine in Group 3 intact rats showed at least 85% dose absorption, with 81.51% of the administered dose recovered in feces and 8.89% in urine. Brilaroxazine represented ~31% of the circulating radioactivity exposure with three primary metabolites- M641a (oxidation + glucuronidation), RP5081 (O-dealkylated acid), and M219 (N-[2,3-dichlorphenyl]-glycine)- accounting for ~29%,~16%, and ~16%, respectively. In Group 1 rat bile, the analysis did not detect brilaroxazine but identified M641a, accounting for 70% of the bile radioactivity or 56% of the dose. In Group 3 intact rat feces, the mono-hydroxylated compound, M465a, was the major metabolite, accounting for 86% of the fecal radioactivity or 71% of the dose. The gut microflora likely converted the glucuronide metabolite, M641a, observed in Group 1 rat bile, to the mono-hydroxylated metabolite M465a, which underwent fecal elimination in Group 3 rats. Glucuronidase hydrolysis of M641a, producing M465a in a near quantitative yield, confirmed this supposition. Conclusions: Following oral administration, brilaroxazine in rats underwent rapid absorption, extensive metabolism, and elimination via hepato-biliary excretion. The primary human metabolites, RP5081 and M219, were among the most commonly circulated in rats. Both humans and rats utilize 465a formation as the major metabolic pathway. These findings confirm that rats are a suitable rodent species for the toxicological evaluations of brilaroxazine. Reviva Pharmaceutical Holdings, Inc.

In vitro metabolism of the analgesic bicifadine in the mouse, rat, monkey, and human

In Vitro Metabolism of E2, G2: Novel Bile Acid-Coupling Camptothecin Analogues, in Rat Liver Microsomes

Computational Investigation of the Bisphenolic Drug Metabolism by Cytochrome P450: What Factors Favor Intramolecular Phenol Coupling

In vitro metabolism of bencycloquidium bromide and its inhibitory effects on human P450 isoenzymes: implication of CYP2D6, CYP2C19 and CYP3A4/5

Comparative in vitro metabolism of 14C-ciclesonide in hepatocytes from the mouse, rat, rabbit, dog, and human

In vitro hepatic metabolism of cediranib, a potent vascular endothelial growth factor tyrosine kinase inhibitor: interspecies comparison and human enzymology

Metabolism of amiodarone (Part III): identification of rabbit cytochrome P450 isoforms involved in the hydroxylation of mono-N-desethylamiodarone

In Vitro Metabolism of Zolmitriptan in Rat Cytochromes Induced with Β-Naphthoflavone and the Interaction Between Six Drugs and Zolmitriptan

Radiolabel uncovers nonintuitive metabolites of AMPAR potentiator BIIB104: Novel release of [ 14 C]cyanide from 2-cyanothiophene and subsequent formation of [ 14 C]thiocyanate

Metabolism and Metabolic Inhibition of Cilnidipine in Human Liver Microsomes.

Stereoselective Metabolism of Bupropion to Active Metabolites in Cellular Fractions of Human Liver and Intestine

Biotransformation of Columbianadin by Rat Hepatic Microsomes and Inhibition of Biotransformation Products on No Production in Raw 264.7 Cells in Vitro

Unique Oxidative Metabolism of Bufalin Generates Two Reactive Metabolites That Strongly Inactivate Human Cytochrome P450 3A

Absorption, Metabolism, and Excretion of Brilaroxazine in Rats

Comparison of the Circulating Metabolite Profile of PF-04991532, a Hepatoselective Glucokinase Activator, Across Preclinical Species and Humans: Potential Implications in Metabolites in Safety Testing Assessment

Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists

Cytochrome P450 2B6 and UDP-Glucuronosyltransferase Enzyme-Mediated Clearance of Ciprofol in Humans: The Role of Hepatic and Extrahepatic Metabolism

[Assessment of biotransformation capacity following oral administration of various model substances as cocktail]

Characterization of Enzymes Involved in Nintedanib Metabolism in Humans

The role of the gut flora in the metabolism of cyclamate

Metabolic profiling of a new synthetic cannabinoid receptor agonist, ADMB-FUBIATA, with human liver microsomes, human primary hepatocytes and human recombinant CYP450 enzymes using LC-quadrupole-orbitrap MS